High-Sensitivity Plasma Testing for Non-small Cell Lung Cancer | GenomeWeb
October 07, 2015
Sponsored by
Personal Genome Diagnostics

High-Sensitivity Plasma Testing for Non-small Cell Lung Cancer


Interim Director, Sidney Kimmel Comprehensive Cancer Center

Vice President, Research & Development, Personal Genome Diagnostics 

This webinar highlights the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

NSCLC is the most common type of lung cancer, accounting for about 80 percent of all lung cancer cases. Approximately 35 percent of NSCLC patients do not have sufficient tissue biopsy material for informative NGS testing due to late-stage diagnosis and difficulties associated with repeat biopsy for real-time monitoring. 

Circulating free DNA (cfDNA) has been proposed as an alternative approach for the detection of actionable mutations in NSCLC. Recent advances in next-generation sequencing of plasma allow for the rapid and affordable identification of driver mutations in NSCLC patients, which have a profound impact on clinical management. 

This online seminar will detail the clinical considerations of NGS-based plasma testing for managing NSCLC patients. 

Sponsored by

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.

Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.